GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Allenex AB (LTS:0O9J) » Definitions » EBITDA

Allenex AB (LTS:0O9J) EBITDA : £1.88 Mil (TTM As of Mar. 2016)


View and export this data going back to . Start your Free Trial

What is Allenex AB EBITDA?

Allenex AB's EBITDA for the three months ended in Mar. 2016 was £0.24 Mil. Its EBITDA for the trailing twelve months (TTM) ended in Mar. 2016 was £1.88 Mil.

During the past 12 months, the average EBITDA Growth Rate of Allenex AB was 9.80% per year. During the past 3 years, the average EBITDA Growth Rate was 39.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 11 years, the highest 3-Year average EBITDA Growth Rate of Allenex AB was 39.70% per year. The lowest was -19.80% per year. And the median was 22.45% per year.

Allenex AB's EBITDA per Share for the three months ended in Mar. 2016 was £0.00. Its EBITDA per share for the trailing twelve months (TTM) ended in Mar. 2016 was £0.02.

During the past 12 months, the average EBITDA per Share Growth Rate of Allenex AB was 9.50% per year. During the past 3 years, the average EBITDA per Share Growth Rate was 39.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per share growth rate using EBITDA per Share data.

During the past 11 years, the highest 3-Year average EBITDA per Share Growth Rate of Allenex AB was 39.60% per year. The lowest was -58.60% per year. And the median was -4.45% per year.


Allenex AB EBITDA Historical Data

The historical data trend for Allenex AB's EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allenex AB EBITDA Chart

Allenex AB Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -8.08 0.96 1.10 2.12 2.19

Allenex AB Quarterly Data
Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16
EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.54 0.41 0.48 0.76 0.24

Competitive Comparison of Allenex AB's EBITDA

For the Biotechnology subindustry, Allenex AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Allenex AB's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Allenex AB's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Allenex AB's EV-to-EBITDA falls into.


Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Allenex AB's EBITDA for the fiscal year that ended in Dec. 2015 is calculated as

Allenex AB's EBITDA was directly provided by GuruFocus' data source Morningstar. For the fiscal year ended in Dec. 2015, Allenex AB's EBITDA was £2.19 Mil.

Allenex AB's EBITDA for the quarter that ended in Mar. 2016 is calculated as

Allenex AB's EBITDA was directly provided by GuruFocus' data source Morningstar. For the quarter ended in Mar. 2016, Allenex AB's EBITDA was £0.24 Mil.

EBITDA for the trailing twelve months (TTM) ended in Mar. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was £1.88 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sometimes companies may have already deducted Depreciation and Amortization from Gross Profit. In this case Depreciation and Amortization needs to be added back when calculating EBITDA.

Allenex AB  (LTS:0O9J) EBITDA Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals Operating Income. Operating Income is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses.. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies. Also Price-to-EBITDA is sometimes used in valuations.


Allenex AB EBITDA Related Terms

Thank you for viewing the detailed overview of Allenex AB's EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Allenex AB (LTS:0O9J) Business Description

Traded in Other Exchanges
N/A
Address
Allenex AB creates life-science companies in collaboration with innovators. The process requires identifying ideas with commercial potential, and then contributing entrepreneurship and capital. Its portfolio consists of twelve companies, four in drug development and biotechnology, and eight in diagnostics and medical technologies. The company portfolio accounts for more than 50 different projects, some nearing the commercialization phase while others are already selling their products of services, in a wide range of therapeutic areas- from HIV and cancer to eye disease and allergies. Its Drug Development and Biotechnology business area is comprised of four companies: Anamar Medical, IMED, Novahep, and Recopharma. Anamar Medical develops drugs and biomarkers for diagnosing and monitoring/predicting chronic joint diseases such as rheumatoid arthritis and osteoarthritis, with five drug candidates' two biomarkets, and two commercial biomarkers. IMED develops human monoclonal antibodies (MAB) that induce or block natural cell death or apoptosis, and intending to develop antibodies for major therapeutic areas, including HIV, cancer, and transplantation. Novahep, in collaboration with the Karolinska Institute, aims to differentiate cell lines of fetal liver stem cells, which can then be used in the transplantation sector. Recopharma develops mucins for the vaccine market and antimicrobial substances to combat bacteria and viruses that may cause eye infection, influenza, and the Norwalk virus. The companies in the Diagnostics and Medical Technology business area include Absorber, Bioresonator, Biovator, Likvor, Olerup, Olerup SSP, Oncolog, Ortoviva, and Pharmacolog. These companies develop products such as the XM-ONE transplantation test, biomedical sensors, allergic reaction testing technology for the pharmaceutical, cosmetic and chemical industries, a diagnostic instrument to measure cerebrospinal fluid pressure (CSF), tools to facilitate the insertion of artificial discs in spinal surgery, and systems to control the content and concentration of liquid pharmaceutical drugs.

Allenex AB (LTS:0O9J) Headlines

No Headlines